8-K Announcements
6Material company update
May 21, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Mar 16, 2026·SEC
Black Diamond Therapeutics, Inc.(BDTX)Earnings, Financials & Key Ratios
BDTX•NASDAQ
4.3× P/E·Price updated Jun 19, 2026
AboutBlack Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$70M
- EBITDA$20M+125.7%
- Net Income$22M+132.1%
- EPS (Diluted)0.39+130.7%
- Gross Margin99.54%
- EBITDA Margin28.85%
- Operating Margin28.39%
- Net Margin31.95%
- ROE22.88%+132.8%
BDTX Key Insights
Black Diamond Therapeutics, Inc. (BDTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 8/9
- ✓FCF machine: 42.3% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Healthy 5Y average net margin of 32.0%
- ✓Trading at only 0.9x book value
✗Weaknesses
- ✗Weak momentum: RS Rating 8 (bottom 8%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BDTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BDTX Price & Volume
Black Diamond Therapeutics, Inc. (BDTX) stock price & volume — 10-year historical chart
Loading chart...
BDTX Growth Metrics
Black Diamond Therapeutics, Inc. (BDTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-948.77%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1366.67%
Return on Capital
10 Years-38.85%
5 Years-41.54%
3 Years-36.61%
Last Year17.33%
BDTX Recent Earnings
Black Diamond Therapeutics, Inc. (BDTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 1/12 qtrs (100%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.16+11.1%
$0.18
Rev
—
$25M
Q2 2026
Mar 16, 2026Metric
Actual
Est
EPS
$0.14+22.2%
$0.18
Rev
—
$9M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.15+31.8%
$0.22
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.19+24.0%
$0.25
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.16vs $0.18+11.1% | —vs $25M |
| Q2 2026 | Mar 16, 2026 | $0.14vs $0.18+22.2% | —vs $9M |
| Q4 2025 | Nov 6, 2025 | $0.15vs $0.22+31.8% | — |
| Q3 2025 | Aug 7, 2025 | $0.19vs $0.25+24.0% | — |
Based on last 12 quarters of dataView full earnings history →
BDTX Peer Comparison
Black Diamond Therapeutics, Inc. (BDTX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 NUVL | 9.08B | 123.43 | -21.10 | -42.78% | ||||
 AUPH | 2.12B | 16.46 | 7.95 | 20.38% | 99.97% | 64.48% | 0.13 | |
 ERAS | 4.25B | 13.67 | -31.07 | -77.01% | 0.14 | |||
 ARVN | 494.88M | 7.67 | -5.99 | -0.3% | -247.54% | -44.39% | 0.02 | |
 MGNX | 262.52M | 4.13 | -3.50 | 0.78% | -44.79% | -147.8% | 1.92 | |
 PRME | 583.39M | 3.23 | -2.39 | 55.28% | -49.18% | -188.82% | 0.96 | |
 CGEM | 923.71M | 15.03 | -4.04 | -51.45% | 0.01 |
Compare BDTX vs Peers
Black Diamond Therapeutics, Inc. (BDTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BDTX Income Statement
Black Diamond Therapeutics, Inc. (BDTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 70M | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - | -100% |
Cost of Goods Sold | 24K | 44K | 47K | 0 | 0 | 0 | 437K | 0 | 325K | 113K |
COGS % of Revenue | - | - | - | - | - | - | - | - | 0.46% | - |
Gross Profit | -24K▲ 0% | -44K▼ 83.3% | -47K▼ 6.8% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | -437K▲ 0% | 0▲ 100.0% | 69.67M▲ 0% | -113K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | 99.54% | - |
Gross Profit Growth % | - | -83.33% | -6.82% | 100% | - | - | - | 100% | - | - |
Operating Expenses | 4.12M | 8.9M | 29.33M | 69.57M | 126.87M | 92.83M | 86.02M | 78.78M | 49.8M | 53.18M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | 71.15% | - |
Selling, General & Admin | 666K | 1.95M | 7.58M | 21.36M | 30.04M | 28.39M | 27.11M | 27.47M | 16.57M | 15.86M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | 23.67% | - |
Research & Development | 3.45M | 6.95M | 21.75M | 48.21M | 96.83M | 64.44M | 58.91M | 51.31M | 33.56M | 30.05M |
R&D % of Revenue | - | - | - | - | - | - | - | - | 47.94% | - |
Other Operating Expenses | -6K | -16K | 0 | 0 | 0 | 0 | 0 | 0 | -325K | 914K |
Operating Income | -4.12M▲ 0% | -8.9M▼ 116.2% | -8.9M▲ 0.0% | -69.57M▼ 681.3% | -126.87M▼ 82.4% | -92.83M▲ 26.8% | -86.46M▲ 6.9% | -78.78M▲ 8.9% | 19.87M▲ 125.2% | -53.27M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | 28.39% | - |
Operating Income Growth % | - | -116.17% | 0% | -681.33% | -82.37% | 26.83% | 6.86% | 8.88% | 125.22% | - |
EBITDA | -4.09M | -8.86M | -8.86M | -68.97M | -126.67M | -92.32M | -86.02M | -78.44M | 20.2M | -53M |
EBITDA Margin % | - | - | - | - | - | - | - | - | 28.85% | - |
EBITDA Growth % | - | -116.36% | 0.03% | -678.71% | -83.66% | 27.12% | 6.82% | 8.82% | 125.75% | -1347.75% |
D&A (Non-Cash Add-back) | 24K | 44K | 47K | 600K | 205K | 508K | 437K | 343K | 325K | 265K |
EBIT | -4.12M | -8.93M | -29.33M | -67.25M | -126.87M | -92.83M | -86.46M | -78.78M | 19.87M | -40.58M |
Net Interest Income | 0 | 0 | 461K | 4.04M | 3.46M | 2.03M | 1.92M | 2.18M | 4.06M | 4.49M |
Interest Income | 0 | 4K | 461K | 4.04M | 3.46M | 2.03M | 1.92M | 2.18M | 4.06M | 4.49M |
Interest Expense | 65K | 0 | 0 | 1K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -483K | -27K | -5.93M | 2.32M | 1.28M | 1.66M | 4.02M | 9.11M | 2.5M | 10.06M |
Pretax Income | -4.6M▲ 0% | -8.93M▼ 94.1% | -35.26M▼ 294.8% | -67.25M▼ 90.7% | -125.6M▼ 86.7% | -91.17M▲ 27.4% | -82.44M▲ 9.6% | -69.68M▲ 15.5% | 22.37M▲ 132.1% | -43.21M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | 31.95% | - |
Income Tax | 0 | -27K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0.3% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -4.6M▲ 0% | -8.93M▼ 94.1% | -35.26M▼ 294.8% | -67.25M▼ 90.7% | -125.6M▼ 86.7% | -91.17M▲ 27.4% | -82.44M▲ 9.6% | -69.68M▲ 15.5% | 22.37M▲ 132.1% | -43.21M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | 31.95% | - |
Net Income Growth % | - | -94.07% | -294.78% | -90.75% | -86.75% | 27.41% | 9.57% | 15.48% | 132.1% | -948.77% |
Net Income (Continuing) | -4.6M | -8.93M | -35.26M | -67.25M | -125.6M | -91.17M | -82.44M | -69.68M | 22.37M | -43.21M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.64▲ 0% | -0.64▲ 0.0% | -1.15▼ 79.7% | -2.04▼ 77.4% | -3.47▼ 70.1% | -2.52▲ 27.4% | -1.88▲ 25.4% | -1.27▲ 32.4% | 0.39▲ 130.7% | -0.76▲ 0% |
EPS Growth % | - | 0% | -79.69% | -77.39% | -70.1% | 27.38% | 25.4% | 32.45% | 130.71% | -1366.67% |
EPS (Basic) | -0.64 | -0.64 | -1.15 | -2.04 | -3.47 | -2.52 | -1.88 | -1.27 | 0.39 | - |
Diluted Shares Outstanding | 7.2M | 13.95M | 35.91M | 32.91M | 36.19M | 36.23M | 43.95M | 55.03M | 57.56M | 57.23M |
Basic Shares Outstanding | 7.2M | 13.95M | 35.91M | 32.91M | 36.19M | 36.23M | 43.95M | 55.03M | 56.87M | 57.23M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BDTX Balance Sheet
Black Diamond Therapeutics, Inc. (BDTX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 7.91M | 51.68M | 155.71M | 319.55M | 215.7M | 127.71M | 134.03M | 101.18M | 132.44M | 122.97M |
Cash & Short-Term Investments | 7.88M | 51.66M | 154.67M | 315.07M | 209.79M | 122.81M | 131.4M | 98.58M | 128.65M | 118.26M |
Cash Only | 7.88M | 51.66M | 154.67M | 34.6M | 65.8M | 34.31M | 56.22M | 36.44M | 20.99M | 30.07M |
Short-Term Investments | 0 | 0 | 0 | 280.46M | 143.99M | 88.49M | 75.18M | 62.14M | 107.66M | 88.19M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 4.9M | 2.63M | 2.6M | 3.79M | 4.71M |
Total Non-Current Assets | 107K | 142K | 2.58M | 10.12M | 31.98M | 28.55M | 24.53M | 21.46M | 10.57M | 9.96M |
Property, Plant & Equipment | 102K | 134K | 164K | 8.79M | 30.74M | 27.38M | 23.71M | 20.4M | 9.67M | 9.1M |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | 7.24x | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 829K | 1.66M |
Other Non-Current Assets | 5K | 8K | 2.42M | 1.33M | 1.24M | 1.17M | 823K | 1.07M | 73K | 29K |
Total Assets | 8.02M▲ 0% | 51.83M▲ 546.1% | 158.29M▲ 205.4% | 329.67M▲ 108.3% | 247.68M▼ 24.9% | 156.25M▼ 36.9% | 158.57M▲ 1.5% | 122.64M▼ 22.7% | 143.01M▲ 16.6% | 132.92M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | 0.49x | 0.00x |
Asset Growth % | - | 546.13% | 205.44% | 108.26% | -24.87% | -36.91% | 1.48% | -22.66% | 16.61% | 17.35% |
Total Current Liabilities | 2.23M | 2.58M | 4.86M | 14.22M | 23.64M | 15.26M | 19.65M | 20.57M | 15.73M | 14.53M |
Accounts Payable | 152K | 416K | 1.96M | 2.54M | 4.11M | 1.88M | 2.32M | 4.01M | 579K | 2.97M |
Days Payables Outstanding | 2.31K | 3.45K | 15.25K | - | - | - | 1.94K | - | 650.26 | 4.28K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.79M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15.15M | 7.77M |
Current Ratio | 3.55x | 20.07x | 32.02x | 22.48x | 9.12x | 8.37x | 6.82x | 4.92x | 8.42x | 8.46x |
Quick Ratio | 3.55x | 20.07x | 32.02x | 22.48x | 9.12x | 8.37x | 6.82x | 4.92x | 8.42x | 8.46x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 12.47M | 64.79M | 200.59M | 7.69M | 28.14M | 25.3M | 22.18M | 18.78M | 15.07M | 14.09M |
Long-Term Debt | 0 | 60.77M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 7.69M | 28.14M | 25.3M | 22.18M | 18.78M | 15.07M | 62.16M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 12.47M | 4.02M | 200.59M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 14.7M | 67.37M | 205.45M | 21.91M | 51.78M | 40.56M | 41.83M | 39.35M | 30.8M | 28.62M |
Total Debt | 12.46M | 60.77M | 0 | 8.74M | 28.46M | 28.14M | 25.3M | 22.19M | 15.07M | 17.88M |
Net Debt | 4.58M | 9.11M | -154.67M | -25.86M | -37.34M | -6.17M | -30.92M | -14.25M | -5.92M | -12.19M |
Debt / Equity | - | - | - | 0.03x | 0.15x | 0.24x | 0.22x | 0.27x | 0.13x | 0.17x |
Debt / EBITDA | - | - | - | - | - | - | - | - | 0.75x | -0.34x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | -0.29x | 0.23x |
Interest Coverage | -63.37x | - | - | -67254.00x | - | - | - | - | - | - |
Total Equity | -6.67M▲ 0% | -15.54M▼ 132.8% | -47.16M▼ 203.4% | 307.76M▲ 752.6% | 195.9M▼ 36.3% | 115.69M▼ 40.9% | 116.74M▲ 0.9% | 83.28M▼ 28.7% | 112.21M▲ 34.7% | 104.3M▲ 0% |
Equity Growth % | - | -132.84% | -203.42% | 752.62% | -36.35% | -40.94% | 0.9% | -28.66% | 34.73% | 57.36% |
Book Value per Share | -0.93 | -1.11 | -1.31 | 9.35 | 5.41 | 3.19 | 2.66 | 1.51 | 1.95 | 1.82 |
Total Shareholders' Equity | -6.67M | -15.54M | -47.16M | 307.76M | 195.9M | 115.69M | 116.74M | 83.28M | 112.21M | 104.3M |
Common Stock | 1K | 1K | 1K | 5K | 5K | 5K | 7K | 7K | 8K | 8K |
Retained Earnings | -6.78M | -15.71M | -50.97M | -118.22M | -243.82M | -334.99M | -417.43M | -487.11M | -464.74M | -473.78M |
Treasury Stock | 56K | 100K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -56K | -100K | 0 | 614K | -414K | -1.82M | -27K | 24K | 101K | -36K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BDTX Cash Flow Statement
Black Diamond Therapeutics, Inc. (BDTX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -2.35M | -8.45M | -24.67M | -52.15M | -100.15M | -85.08M | -66.72M | -62.3M | 29.61M | -34.03M |
Operating CF Margin % | - | - | - | - | - | - | - | - | 42.31% | - |
Operating CF Growth % | - | -259.59% | -191.86% | -111.34% | -92.05% | 15.04% | 21.59% | 6.62% | 147.53% | 4.24% |
Net Income | -4.6M | -8.93M | -35.26M | -67.25M | -125.6M | -91.17M | -82.44M | -69.68M | 22.37M | -43.21M |
Depreciation & Amortization | 24K | 44K | 47K | 52K | 205K | 508K | 437K | 343K | 325K | 265K |
Stock-Based Compensation | 5K | 64K | 3.64M | 7.76M | 14.04M | 12.2M | 9.6M | 10.63M | 6.63M | 3.19M |
Deferred Taxes | 412K | 0 | 0 | 1.73M | 2.18M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 66K | 15K | 6.43M | 524K | 2.01M | 3.28M | 2M | -905K | 9.02M | 12.25M |
Working Capital Changes | 1.74M | 354K | 463K | 5.04M | 7.02M | -9.9M | 3.69M | -2.69M | -8.73M | -6.52M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -59K | 264K | 1.45M | 1.07M | 1.57M | -2.23M | 597K | 1.68M | -3.43M | 341K |
Cash from Investing | -77K | -76K | -21K | -281.69M | 130.61M | 53.37M | 16.35M | 16.97M | -44.91M | -33.95M |
Capital Expenditures | -77K | -76K | -21K | -142K | -2.71M | -192K | -33K | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 118K | 2.7M | 9K | 0 | 94K | 27K | 14K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | -118K | -2.7M | 0 | 95K | 0 | 74K | 74K |
Cash from Financing | 9.97M | 52.31M | 127.76M | 214.94M | 729K | 177K | 71.93M | 25.55M | -146K | -363K |
Debt Issued (Net) | -50K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 52.31M | 129.5M | 213.84M | 729K | 177K | 71.85M | 24.49M | -146K | -178K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 10.02M | 0 | -1.74M | 1.1M | 0 | 0 | 82K | 1.05M | 0 | -185K |
Net Change in Cash | 7.55M▲ 0% | 43.78M▲ 480.2% | 103.06M▲ 135.4% | -118.89M▼ 215.4% | 31.19M▲ 126.2% | -31.54M▼ 201.1% | 21.56M▲ 168.4% | -19.79M▼ 191.8% | -15.44M▲ 22.0% | -68.34M▲ 0% |
Free Cash Flow | -2.43M▲ 0% | -8.53M▼ 251.3% | -24.7M▼ 189.5% | -52.29M▼ 111.7% | -102.86M▼ 96.7% | -85.27M▲ 17.1% | -66.75M▲ 21.7% | -62.3M▲ 6.7% | 29.61M▲ 147.5% | -34.03M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | 42.31% | - |
FCF Growth % | - | -251.32% | -189.51% | -111.74% | -96.71% | 17.1% | 21.72% | 6.66% | 147.53% | -225.88% |
FCF per Share | -0.34 | -0.61 | -0.69 | -1.59 | -2.84 | -2.35 | -1.52 | -1.13 | 0.51 | -0.59 |
FCF Conversion (FCF/Net Income) | 0.51x | 0.95x | 0.70x | 0.78x | 0.80x | 0.93x | 0.81x | 0.89x | 1.32x | 0.79x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BDTX Key Ratios
Black Diamond Therapeutics, Inc. (BDTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -51.61% | -49.87% | -58.52% | -70.94% | -69.67% | 22.88% | -36.37% |
Return on Invested Capital (ROIC) | - | - | -130.33% | -43.21% | -51.94% | -66.39% | -76.31% | 17% | -36.9% |
Gross Margin | - | - | - | - | - | - | - | 99.54% | - |
Net Margin | - | - | - | - | - | - | - | 31.95% | - |
Debt / Equity | - | - | 0.03x | 0.15x | 0.24x | 0.22x | 0.27x | 0.13x | 0.17x |
Interest Coverage | - | - | -67254.00x | - | - | - | - | - | - |
FCF Conversion | 0.95x | 0.70x | 0.78x | 0.80x | 0.93x | 0.81x | 0.89x | 1.32x | 0.79x |
Revenue Growth | - | - | - | - | - | - | - | - | -100% |
Related:BDTX Dividend History·BDTX Revenue History·BDTX Price History·BDTX P/E History·BDTX Financial Ratios·BDTX Institutional Holders
BDTX SEC Filings & Documents
Black Diamond Therapeutics, Inc. (BDTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
BDTX Frequently Asked Questions
Black Diamond Therapeutics, Inc. (BDTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Black Diamond Therapeutics, Inc. (BDTX) reported $70.0M in revenue for fiscal year 2025.
Black Diamond Therapeutics, Inc. (BDTX) grew revenue by 0.0% over the past year. Growth has been modest.
Black Diamond Therapeutics, Inc. (BDTX) reported a net loss of $43.2M for fiscal year 2025.
Dividend & Returns
Black Diamond Therapeutics, Inc. (BDTX) has a return on equity (ROE) of 22.9%. This is excellent, indicating efficient use of shareholder capital.
Black Diamond Therapeutics, Inc. (BDTX) had negative free cash flow of $34.0M in fiscal year 2025, likely due to heavy capital investments.